Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Common Equity (2021 - 2025)

Prime Medicine filings provide 5 years of Common Equity readings, the most recent being $120.9 million for Q4 2025.

  • On a quarterly basis, Common Equity fell 21.08% to $120.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $120.9 million, a 21.08% decrease, with the full-year FY2025 number at $120.9 million, down 21.08% from a year prior.
  • Common Equity hit $120.9 million in Q4 2025 for Prime Medicine, down from $161.8 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $316.3 million in Q4 2022 to a low of -$223.1 million in Q3 2022.
  • Median Common Equity over the past 5 years was $143.1 million (2023), compared with a mean of $86.7 million.
  • The widest YoY moves for Common Equity: up 302.43% in 2022, down 136.29% in 2022.
  • Prime Medicine's Common Equity stood at -$156.2 million in 2021, then soared by 302.43% to $316.3 million in 2022, then plummeted by 57.92% to $133.1 million in 2023, then grew by 15.09% to $153.1 million in 2024, then dropped by 21.08% to $120.9 million in 2025.
  • The last three reported values for Common Equity were $120.9 million (Q4 2025), $161.8 million (Q3 2025), and $60.9 million (Q2 2025) per Business Quant data.